On 19 August 2026, Moderna and MSD announced the first positive Phase 3 readout for a personalised mRNA cancer therapy. The same month, Google Trends reached maximum possible global search volume. This report documents how Zorthex had the phenomenon in its dataset before the breakout — not because it predicted it, but because it was measuring the gap.
The gap between the three sources is the signal. In this case, all three converged in August 2026 — Google Trends at maximum, Wikipedia spiking on the exact announcement date, Reddit crossing from specialist to mainstream. This is not Dual-Velocity (where specialists know and the public doesn't): this is full convergence — the window has closed. The question is whether it stays closed.
| Field | Data |
|---|---|
| Trial | INTerpath-001 (NCT05933577) |
| Sponsor | Moderna / MSD (Merck) |
| Design | Phase 3, randomised, double-blind |
| Population | 1,137 patients with resected high-risk cutaneous melanoma (stage IIB–IV) |
| Treatment | mRNA-4157/V940 (personalised neoantigen vaccine) + pembrolizumab (Keytruda) vs Keytruda alone |
| Primary endpoint | Recurrence-free survival (RFS) — met |
| Key secondary | Distant metastasis-free survival (DMFS) — met |
| Announcement | 19 August 2026 |
| Significance | First Phase 3 proof-of-principle that personalised mRNA cancer vaccines work. First regimen to outperform Keytruda alone in adjuvant melanoma setting. |
| Data status | Not yet peer-reviewed; not yet presented at conference (as of report date) |
| Source level | Level A — Moderna/MSD press release, 19 August 2026 |
When the public reached 100/100 in August 2026, the specialist layer had been building for over a decade:
| Company | Pipeline | Status by Aug 2026 |
|---|---|---|
| Moderna/MSD | mRNA-4157/V940 (personalised neoantigen) | Phase 3 positive (INTerpath-001). Phase 2 5-year data published (Jan 2026). Melanoma, NSCLC, renal, bladder in pipeline. |
| BioNTech | Autogene cevumeran + multiple candidates | Multiple Phase 3 trials planned (15 in oncology by year-end 2026). €17.2B cash committed. Pancreatic cancer, melanoma, CRC programmes active. |
| CureVac | CV8102 (RNA-based immunostimulant) | Phase 1/2 in solid tumours. |
The clinical infrastructure was at scale. The investment was committed. The specialist community — oncologists, immunologists, clinical trial networks — had been working on this for years. Google Trends during most of this: under 25/100. The public did not search because it did not know the vocabulary. Not "mRNA vaccine" (which they associated with COVID), but "mRNA cancer vaccine" — a term that required a conceptual leap the public had not yet made.
1. The phenomenon was in the Zorthex dataset as PRE (pre-emergent) before the breakout occurred. The dataset caught it — not as a prediction, but as a documented gap between specialist activity and public search intent.
2. The trigger (INTerpath-001, 19 August 2026) is verified to the day across two independent sources: Google Trends reached 100/100 in the same month; Wikipedia pageviews for "mRNA vaccine" spiked from ~300/day to 1,301/day on the day after the announcement; "Cancer vaccine" peaked at 828/day on the announcement day itself.
3. 14 consecutive months above structural threshold (25/100) — promoted to STRUCTURAL. This is the only PRE→STRUCTURAL transition in the 71-case dataset.
4. L ≈ 139 months (from first clinical trial, January 2015, to peak attention, August 2026) — provisional under Rock Rule.
1. Whether the breakout consolidates or retreats. The PQC case (L=91) reached 100/100 in June 2026 and retreated to 24 by August — spike and retreat. mRNA may follow the same pattern or may hold. The next three months will determine this.
2. Clinical efficacy. This report measures attention, not medicine. The INTerpath-001 data is not yet peer-reviewed. A negative follow-up would likely produce a rapid attention decline.
3. Investment timing. The report does not recommend any position. It documents the gap between specialist activity and public awareness — and notes that the gap has now closed.
| Trigger | Expected effect | Timeframe |
|---|---|---|
| INTerpath-001 peer-reviewed publication and conference presentation | Sustained attention if data holds. Rapid decline if questions arise about methodology or effect size. | Q4 2026 – Q1 2027 |
| BioNTech Phase 3 readouts (autogene cevumeran, pancreatic/CRC) | If positive: confirms platform, attention broadens beyond melanoma. If negative: attention fragments ("only works for melanoma"). | Q4 2026 – 2027 |
| FDA regulatory pathway decision (accelerated approval for mRNA-4157) | Institutional consolidation — the term enters regulatory vocabulary. | 2027 |
| GT score September–November 2026 | If stays above 25: STRUCTURAL confirmed. If drops below: spike and retreat, same as PQC. | Immediate |
The Zorthex dataset contains 71 verified cases across seven domains. mRNA cancer vaccine is unique in three ways:
1. Only PRE→STRUCTURAL transition. No other case has moved from pre-emergent classification to maximum attention in a single observation cycle.
2. Vocabulary transfer, not Dual-Velocity. The public knew both components ("mRNA" and "cancer vaccine") separately. The lag was in the compound term — a conceptual bridge, not an information gap. This is a new category in the framework.
3. Real-time capture. The case was in the dataset before the breakout, promoted during the breakout, and documented within weeks. This is the fastest turnaround from observation to publication in the project's history.
| Source | Level | Access |
|---|---|---|
| Moderna/MSD press release, INTerpath-001 Phase 3, 19 Aug 2026 | A | Public (modernatx.com) |
| ClinicalTrials.gov NCT05933577 | A | Public |
| Google Trends CSV "mRNA cancer vaccine" (all, worldwide) | A | Locked 3 Sep 2026 |
| Wikipedia pageviews API (MRNA_vaccine, Cancer_vaccine) daily Aug 2026 | A | Locked 12 Sep 2026 |
| Ars Technica, 22 Jan 2026: 5-year follow-up data | B | Public |
| Seeking Alpha, 17 Oct 2025: Moderna cancer vaccine analysis | B | Public |
| BioNTech investor presentation, J.P. Morgan Healthcare Conf., Jan 2026 | A | Public (investors.biontech.de) |